Nitric oxide in patients with transitional bladder cancer.

Area of Science:

• Oncology
• Urology
• Biochemistry

Background:

• Identifying patients with superficial transitional bladder carcinoma (TBC) at high risk of recurrence or progression is a clinical challenge.
• Inducible nitric oxide synthase (iNOS) expression has been observed in urinary bladder cancers.
• iNOS produces high concentrations of nitric oxide (NO), suggesting potential for elevated urinary NO in TBC patients.

Purpose of the Study:

• To determine and compare urine nitric oxide (NO) levels in patients with transitional bladder carcinoma (TBC).
• To compare urine NO levels between TBC patients, healthy controls, and patients with other non-related tumors.
• To examine inducible nitric oxide synthase (iNOS) expression in bladder cancer tissue.

Main Methods:

• Evaluated urine NO levels using Griess reagent in patients with TBC (n=33), gynecological tumors (GT, n=19), TBC patients with no evidence of disease (NED, n=19), and healthy subjects (n=39).
• Expressed urine NO levels as microM NO(2)(-)/100 mg creatinine.
• Detected iNOS expression in bladder tumors via Western blot.

Main Results:

• TBC patients exhibited significantly higher median urine NO levels (4.2 microM) compared to healthy individuals (2.1 microM), NED group (1.7 microM), and GT patients (2.0 microM) (P=0.000).
• Inducible nitric oxide synthase (iNOS) was detected in 52% (13/25) of examined bladder tumors.
• A wide range of urine NO levels was observed within the TBC group (2.1-91.6 microM).

Conclusions:

• Elevated urine nitric oxide (NO) levels show potential as a biomarker for transitional bladder carcinoma (TBC) patients.
• Further research with a larger cohort is warranted to validate these findings.
• The study suggests a possible role for NO in TBC pathogenesis and detection.